Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin
Phase 3
Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin is one of 12 therapeutic programs targeting Platinum-resistant Ovarian Cancer. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
13 competitors in Platinum-Resistant Ovarian Cancer
#DrugCompanyPhaseTrials
1Gemzar
Johnson & JohnsonPhase 3
Taxol
TevaPhase 3
Hycamtin
MMeitheal
Phase 3
Avastin
BBio-Thera Solutions
Phase 3
Pegylated Liposomal Doxorubicin
Merck & Co.Phase 3
Rina-S
GenmabPhase 3
N-803
IImmunityBio, Inc.
Phase 2
Olvimulogene Nanivacirepvec
GGenelux Corporation
Phase 3
Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin
GGenelux Corporation
Phase 3
M-CENK
IImmunityBio, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Platinum-resistant Ovarian Cancer1 trial
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]
- Company
- GGenelux Corporation